Advertisement
Trivitron is offering a wide range of Newborn screening assays already in the market through the Labsystems diagnostics brand, among those areTSH, PKU, 17OHP, G6PD, Galactose and Toxoplasmi gondii. Together with its fully automated NS2400 platform, Trivitronhas launchedtwo new products to complement its newborn screening panel. Neonatal IRT can detect disorders affecting the lungs, pancreas, intestine and liver. Whereas, Neonatal Toxoplasma gondii IgM can detect neurological and visual disabilities. With Newborn screening tests, the parents can start taking precautions in the early stages of life and prevent the child from life-long disorders. Majority of infants infected in utero are asymptomatic at birth, particularly if maternal infection occurs during third trimester, with sequel appearing later in life. Congenital toxoplasmosis results in severe generalized or neurological disease in about 20% to 30% of the infants infected in utero; approximately 10% exhibit visual involvement only and the remainder are asymptomatic at birth.
Advertisement
Dr. GSK Velu, Founder and Managing Director of Trivitron Group of companies said, “Trivitron Healthcare is taking strong steps towards women and child healthcare diagnosis. The thought behind adding two critical tests to the kit is to eradicate detected problems in the newborn at early stages for better lifestyle and to live a carefree life. Trivitron is known for its innovation in medical technology sector and making it available and affordable to larger section of the population across the globe”.
If untreated during the early stages, problems will start appearing during their teens. Brain and nervous system damage ranges from very mild to severe, and may include Seizures and Intellectual disability.
